Coagulation factors and COVID-19 severity: Mendelian randomization analyses and supporting evidence
Coagulation factors and COVID-19 severity: Mendelian randomization analyses and supporting evidence
Abstract BackgroundThe evolving pandemic of COVID-19 is arousing alarm to public health. According to epidemiological and observational studies, coagulopathy was frequently seen in severe COVID-19 patients, yet the causality from specific coagulation factors to COVID-19 severity and the underlying mechanism remain elusive. MethodsFirst, we assessed causal relationship between 12 coagulation factors and severe COVID-19 illness based on Mendelian randomization (MR) analyses. Second, we curated clinical evidence supporting causal associations between COVID-19 severity and particular coagulation factors which showed significant results in MR analyses. Third, we validated our results in an independent cohort from UK Biobank (UKBB) using polygenic risk score (PRS) analysis and logistic regression model. For all MR analyses, summary-level data from genome-wide association studies (GWAS) were used to ascertain genetic effects on exposures against disease risk. ResultsWe revealed that genetic predisposition to the antigen levels of von Willebrand factor (VWF) and the activity levels of its cleaving protease ADAMTS13 were causally associated with COVID-19 severity, wherein elevated VWF antigen level and lowered ADAMTS13 activity lead to increased risk of severe COVID-19 illness. No significant causal association of tPA, PAI-1, D-dimer, FVII, PT, FVIII, FXI, aPTT, FX or ETP with COVID-19 severity was observed. In addition, as an independent factor, VWF PRS explains a 31% higher risk of severe COVID-19 illness in the UKBB cohort (P = 0.047, OR per SD increase = 1.31, 95% CI: 1.00-1.71). In combination with age, sex, BMI and several pre-existing disease statues, our model can predict severity risks with an AUC of 0.70. ConclusionTogether with the supporting evidence of recent retrospective cohort studies and independent validation based on UKBB data, our results suggested that the associations between coagulation factors VWF/ADAMTS13 and COVID-19 severity are essentially causal, which illuminates one of possible mechanisms underlying COVID-19 severity and guides development of treatment strategy for COVID-19.
Yang Hongxi、Li Mulin Jun、Liu Zipeng、Wang Jianhua、Zhou Yao
Department of Pharmacology, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University||Department of Health Service Management, School of Public Health, Tianjin Medical UniversityThe Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University||Department of Pharmacology, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University||Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical UniversityCentre for PanorOmic Sciences-Genomics and Bioinformatics Cores, The University of Hong KongThe Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University||Department of Pharmacology, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical UniversityThe Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University||Department of Pharmacology, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University
医学研究方法基础医学内科学
Yang Hongxi,Li Mulin Jun,Liu Zipeng,Wang Jianhua,Zhou Yao.Coagulation factors and COVID-19 severity: Mendelian randomization analyses and supporting evidence[EB/OL].(2025-03-28)[2025-04-30].https://www.medrxiv.org/content/10.1101/2020.11.20.20235440.点此复制
评论